Smith & Nephew AGM Approves All Resolutions Amid Pushback on Pay Plans
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Smith & Nephew Snats ( (SNN) ) is now available.
On 6 May 2026, Smith & Nephew reported that all resolutions at its Annual General Meeting were passed by shareholders, including approval of the audited accounts, a final dividend, the re-election and election of all nominated directors, and the reappointment of Deloitte as auditor. Shareholders also renewed authorities to allot shares, disapply pre-emption rights, repurchase shares, and hold general meetings on 14 days’ notice, while adopting new Articles of Association and approving a 2026 global employee share purchase plan.
However, support was notably weaker for the Directors’ Remuneration Policy and the 2026 Performance Share Plan, which both received less than 80% backing, highlighting investor unease over aspects of executive pay. The board, which had undertaken extensive pre-AGM consultation, has committed to further engagement with shareholders and proxy advisers and to provide an update within six months, signalling a need to address governance and compensation concerns despite broad endorsement of its wider capital and governance framework.
The most recent analyst rating on (SNN) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company focused on orthopaedics, sports medicine and advanced wound management. Listed in both London and the U.S., it serves global healthcare markets with surgical devices, implants and related solutions for hospitals and clinicians.
Average Trading Volume: 923,191
Technical Sentiment Signal: Hold
Current Market Cap: $13.24B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.
